饮食中的黄酸盐摄入量和老年人轻度认知障碍的风险:一项病例对照研究
Quanri Liu1, Rui Zhang1, Yujiao Chen2
1Department of Nutrition, Beijing Luhe Hospital, Capital Medical University, Beijing, China.
Nutrition and metabolic insights
|November 4, 2024
概括
摄入较高的某些类黄类药物,如凯姆菲罗尔和米瑞丁,可能会防止轻度认知障碍 (MCI). 相反,较高的皮奥尼丁摄入量与增加MCI风险有关,一些黄类药物可能会保持血脑屏障的完整性.
科学领域:
- 营养神经科学 营养神经科学
- 认知健康 认知健康
- 饮食流行病学 饮食流行病学
背景情况:
- 轻度认知障碍 (MCI) 构成了越来越大的公共卫生挑战.
- 了解可修改的风险因素,如饮食,对于预防至关重要.
- 黄类药物,强大的植物化合物,越来越多地被认为具有神经保护的潜力.
研究的目的:
- 调查饮食中的黄酸盐摄入量与患MCI的风险之间的关联.
- 探索特定的黄类子类和MCI发病率之间的关系.
- 为了检查血脑屏障 (BBB) 完整性的潜在作用,如S100β水平所示,在调解这些效应.
主要方法:
- 采用了一种匹配的病例控制研究设计.
- 通过使用经过验证的食物频率调查问卷来评估饮食中的黄类素摄入量.
- 逻辑回归和皮尔森相关性分析被用来评估关联,血液中S100β度被测量为BBB完整性的标志物.
主要成果:
- 与对照人群相比,患有MCI的个体的总黄类,异黄类,黄类,kaempferol和myricetin摄入量明显较低.
- 摄入大量的总类黄素,异黄,甲,和myricetin与降低MCI的风险有关.
- 较高的皮奥尼丁摄入量与MCI风险呈正相关性,而凯姆菲罗尔和米瑞的摄入量与血液S100β水平呈负相关性.
结论:
- 饮食中摄入特定的黄素,包括异黄,凯姆菲罗尔和米瑞素,可能会提供对MCI的保护.
- 尼丁的摄入似乎与MCI的风险增加有关.
- 凯姆菲罗尔和密瑞可以通过维持血脑屏障的完整性来发挥其认知效益.
更多相关视频
09:50Biosynthesis of a Flavonol from a Flavanone by Establishing a One-pot Bienzymatic Cascade
Published on: August 14, 2019
9.3K
14:39Semi-Targeted Ultra-High-Performance Chromatography Coupled to Mass Spectrometry Analysis of Phenolic Metabolites in Plasma of Elderly Adults
Published on: April 22, 2022
3.8K
相关概念视频
Cancer Prevention
6.1K
Several factors can increase the risk of cancer in an individual. About 50% of cancer cases can be prevented by adopting a healthy lifestyle, regular exercise, eating healthy, and following a modest cancer prevention diet. Epidemiological studies have consistently shown that populations with vegetable and fruit-rich diets have reduced the incidence of cancer. On the other hand, populations who have a diet rich in animal fat, red meat, junk food, or high calories are predisposed to cancer.
Some...
Some...
6.1K
Dementia
97
Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual....
The progression of dementia is generally gradual....
97
Cognitive Development During Adulthood
58
Cognitive development continues throughout adulthood, undergoing significant shifts across early, middle, and late stages. Individual transition occurs from adolescent idealism to pragmatic and adaptable thinking in early adulthood. During this period, individuals learn to integrate personal beliefs with the recognition that other perspectives are equally valid. Exposure to the complexities of modern society, diverse experiences, and higher education contribute to this adaptive thought process,...
58
Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists
98
Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function.
98
Alzheimer's Disease: Overview
449
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
449
